[go: up one dir, main page]

AR022405A1 - Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos - Google Patents

Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos

Info

Publication number
AR022405A1
AR022405A1 ARP000100291A ARP000100291A AR022405A1 AR 022405 A1 AR022405 A1 AR 022405A1 AR P000100291 A ARP000100291 A AR P000100291A AR P000100291 A ARP000100291 A AR P000100291A AR 022405 A1 AR022405 A1 AR 022405A1
Authority
AR
Argentina
Prior art keywords
vla
derivatives
pyroglutamic acid
adhesion
compounds
Prior art date
Application number
ARP000100291A
Other languages
English (en)
Original Assignee
Wyeth Corp
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Elan Pharm Inc filed Critical Wyeth Corp
Publication of AR022405A1 publication Critical patent/AR022405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen derivados de ácido piroglutámico de formula (1) en donde R1, R2, R3, R4 y W tienen el significado dado en la memoria descriptiva, y compuestosrelacionados que se adhieren a VLA-4. Algunos de estos compuestos inhiben también la adhesion de leucocitos y en particular la adhesion de leucocitosintermediada por VLA-4. Dichos compuestos son utiles para el tratamiento de enfermedades inflamatorias en un paciente mamífero por ejemplo en un ser humano talcomo asma, enfermedad de Alzheimer, ateroesclerosis, demencia causada por SIDA, diabetes, enfermedad inflamatoria intestinal, artritis reumatoide, trasplantade tejidos, metástasis de tumores e isquemia de miocardio. Los compuestos pueden administrarse también para el tratamiento de enfermedades cerebralesinflamatorias tales como esclerosis multiple. Asimismo se describen composiciones farmacéuticas que comprenden dichos derivados del ácido piroglutámico y eluso de los mismos para la manufactura de agentes y de medicamentos.
ARP000100291A 1999-01-26 2000-01-24 Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos AR022405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23866199A 1999-01-26 1999-01-26

Publications (1)

Publication Number Publication Date
AR022405A1 true AR022405A1 (es) 2002-09-04

Family

ID=22898814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100291A AR022405A1 (es) 1999-01-26 2000-01-24 Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos

Country Status (12)

Country Link
EP (2) EP1144435B1 (es)
JP (1) JP2002535341A (es)
CN (1) CN1195773C (es)
AR (1) AR022405A1 (es)
AT (1) ATE323102T1 (es)
AU (1) AU2623800A (es)
CA (1) CA2358093A1 (es)
DE (1) DE60027268T2 (es)
ES (1) ES2262504T3 (es)
HK (1) HK1046146B (es)
TW (1) TWI224110B (es)
WO (1) WO2000043413A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144435B1 (en) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
JP5401218B2 (ja) * 2009-09-03 2014-01-29 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN109180552B (zh) * 2018-09-26 2021-10-26 沈阳药科大学 取代的5-氧代吡咯烷类衍生物及其制备方法和应用
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
HRP20250191T1 (hr) 2018-10-30 2025-04-11 Gilead Sciences, Inc. Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69530392D1 (de) * 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
EP0910575B1 (en) * 1996-06-21 2002-09-25 Takeda Chemical Industries, Ltd. Method for producing peptides
KR20010022406A (ko) * 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
EP1144435B1 (en) * 1999-01-26 2006-04-12 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Also Published As

Publication number Publication date
WO2000043413A3 (en) 2000-11-30
CN1195773C (zh) 2005-04-06
AU2623800A (en) 2000-08-07
ATE323102T1 (de) 2006-04-15
DE60027268D1 (de) 2006-05-24
HK1046146A1 (en) 2002-12-27
CN1344274A (zh) 2002-04-10
ES2262504T3 (es) 2006-12-01
EP1144435A2 (en) 2001-10-17
EP1612215A1 (en) 2006-01-04
DE60027268T2 (de) 2007-03-15
CA2358093A1 (en) 2000-07-27
EP1144435B1 (en) 2006-04-12
TWI224110B (en) 2004-11-21
HK1046146B (zh) 2005-07-29
WO2000043413A2 (en) 2000-07-27
JP2002535341A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
ES2568629T3 (es) Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
IL164225A (en) Derivatives of benzensulfonyl - methyl - amino-pyrimidin - 4 - ylamino, pharmaceutical compositions comprising them and their use for the manufacture of medicaments for treating diseases mediated by alpha 4 integrin and a process for their preparation
DE69830806T2 (de) Integrinrezeptor antagonisten
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
DE69622532T2 (de) Glycoprotein iib/iiia-antagonisten
AR014903A1 (es) Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
AR009382A1 (es) Derivados de acidos orto-sulfonamido aril hidroxamicos como inhibidores de la metaloproteinasa de matriz y tace, composiciones que los contienen y uso delos mismos para la preparacion de un medicamento.
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
KR20170003563A (ko) 연골형성을 유도하기 위한 화합물 및 조성물
WO2013052263A2 (en) Antifungal compounds
DE69219807T2 (de) Thienopyridinderivate und diese enthaltende pharmazeutische Zubereitungen
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
WO2013040527A1 (en) Antimicrobial compounds
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
AR029178A1 (es) Compuesto antagonista selectivo del receptor de adenosina a2b, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
ATE264298T1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
CN100418525C (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物
AR029461A1 (es) Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento
US20130338372A1 (en) Substituted Imidazoline Compounds
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
JP3122161B2 (ja) γ−ラクトン免疫抑制剤
AR029611A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4

Legal Events

Date Code Title Description
FB Suspension of granting procedure